Phase I trial of imexon, Inj. plus gemcitabine in patients with advanced previously untreated pancreatic adenocarcinoma

被引：0
|
作者：
Cohen, S. J.
Zalupski, M.
Modiano, M.
Conkling, P.
Mahadevan, D.
Wong, L.
Smith, D.
Dorr, R. T.
Boytim, M.
Hersh, E. M.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Arizona Oncol Associates, Tucson, AZ USA
[4] Virginia Oncol Associates, Norfolk, VA USA
[5] Arizona Canc Ctr, Tucson, AZ USA
[6] Scott & White Mem Hosp & Clin, Temple, TX USA
[7] Northwest Canc Specialists, Vancouver, WA USA
[8] Univ Arizona, Ctr Canc, Tucson, AZ USA
[9] AmpliMed Corp, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15058
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I trial of Amplimexon™ (imexon, inj.) in patients with advanced solid tumors.
    Dragovich, T
    Mendelson, D
    Gordon, M
    Wong, L
    Dorr, R
    Chow, S
    Grenier, K
    Hersh, E
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9122S - 9122S
  • [2] Phase I study of Amplimexon™ (imexon, inj.) in patients with advanced solid tumors and lymphomas:: final report
    Dragovich, T.
    Mendelson, M.
    Modiano, M.
    Gordon, M.
    Grenier, K.
    Dorr, R.
    Hersh, E.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 132 - 132
  • [3] Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma
    Eckel, F
    Schmelz, R
    Erdmann, J
    Mayr, M
    Lersch, C
    [J]. CANCER INVESTIGATION, 2003, 21 (05) : 690 - 694
  • [4] Evofosfamide combined with gemcitabine/nabpaclitaxel in patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma (PAC): Results of a phase I trial
    Borad, Mitesh J.
    Kwak, Eunice Lee
    Wang-Gillam, Andrea
    Ibrahim, Ayman
    Aldridge, Julie
    Olszanski, Anthony J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Park, Byeong-Bae
    Park, Joon Oh
    Lee, Hyo Rak
    Lee, Jeeyun
    Choi, Dong Wook
    Choi, Seong-Ho
    Heo, Jin Seok
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lim, Do Hoon
    Park, Young Suk
    Lim, Ho-Yeong
    Kang, Won Ki
    Park, Keunchil
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (04) : 489 - 494
  • [6] A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Byeong-Bae Park
    Joon Oh Park
    Hyo Rak Lee
    Jeeyun Lee
    Dong Wook Choi
    Seong-Ho Choi
    Jin Seok Heo
    Jong Kyun Lee
    Kyu Taek Lee
    Do Hoon Lim
    Young Suk Park
    Ho-Yeong Lim
    Won Ki Kang
    Keunchil Park
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 60 : 489 - 494
  • [7] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Jaime Feliu
    Mónica Jorge Fernández
    Teresa Macarulla
    Bartomeu Massuti
    Ana Albero
    José Federico González González
    Guillermo Quintero-Aldana
    Juan Ignacio Delgado-Mingorance
    Ana Fernández Montes
    Carmen García Piernavieja
    Manuel Valladares-Ayerbes
    Ana María López Muñoz
    Rebeca Mondéjar Solís
    Pilar Vicente
    Esther Casado Gonzalez
    Irene González Cebrián
    Guillermo López-Vivanco
    [J]. Cancer Chemotherapy and Pharmacology, 2021, 87 : 543 - 553
  • [8] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Feliu, Jaime
    Jorge Fernandez, Monica
    Macarulla, Teresa
    Massuti, Bartomeu
    Albero, Ana
    Gonzalez Gonzalez, Jose Federico
    Quintero-Aldana, Guillermo
    Ignacio Delgado-Mingorance, Juan
    Fernandez Montes, Ana
    Garcia Piernavieja, Carmen
    Valladares-Ayerbes, Manuel
    Lopez Munoz, Ana Maria
    Mondejar Solis, Rebeca
    Vicente, Pilar
    Casado Gonzalez, Esther
    Gonzalez Cebrian, Irene
    Lopez-Vivanco, Guillermo
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 543 - 553
  • [9] Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma
    Baize, N
    Abu Shalaa, A
    Berthier, F
    Demarquay, JFO
    Bernard, JL
    Rahiu, A
    Piche, T
    Huet, PM
    Ran, A
    Caroli-Bosc, FX
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2005, 29 (10): : 1006 - 1009
  • [10] A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity
    Cohen, S. J.
    Zalupski, M. M.
    Modiano, M. R.
    Conkling, P. R.
    Patt, Y. Z.
    Davis, P.
    Dorr, R. T.
    Boytim, M. L.
    Hersh, E. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345